Purpose: Despite the availability of a broad range of treatments for epilepsy, a significant proportion of patients have ongoing seizures.
Introduction
Although numerous new antiepileptic drugs (AEDs) have been introduced over the last decades, offering advantages in terms of tolerability and drug interactions, most clinical trials and meta-analyses have failed to demonstrate any significant superiority in terms of efficacy of these newer AEDs as compared to older AEDs [1] [2] [3] . Also, it is well established that seizure response rates to add-on AED treatment decrease with subsequent AED trials [4] [5] [6] . For these reasons, overall drug response rates in patients with epilepsy have not increased significantly over the last decades [7, 8] . On the other hand, several surgical treatment options have improved epilepsy outcome for patients with drug resistant epilepsy (DRE). Resective surgery is superior to continued drug treatment, especially in patients with temporal lobe epilepsy and an identified structural lesion [9] . Additionally, established (e.g. vagal nerve stimulation (VNS), radiosurgery) and emerging (e.g. responsive neurostimulation, deep brain stimulation (DBS), stereotactic laser ablation) techniques may offer benefit for patients who are unsuitable candidates for resective surgery [10] . Although the literature abounds with studies of seizure outcome following different treatment procedures for patients with DRE, these have mostly addressed specific treatment modalities (e.g. AED treatment) or specific subgroups of patients [11, 12] . An important and unanswered clinical question however is which proportion of patients with DRE are ultimately rendered seizure free by currently available treatments.
In this study, we report treatment trajectories of patients with DRE and estimate the overall impact on long-term seizure outcome of the combined effect of various pharmacological and surgical treatment modalities. Additionally, we provide a detailed characterization of patients with ongoing seizures.
Methods
Adult patients with epilepsy were recruited consecutively through outpatient clinics and hospitalizations at two of the four reference centers for DRE in Belgium between October 2004 and June 2009 (UZ Gasthuisberg, Leuven) and October 2004 and April 2017 (Hôpital Erasme, Brussels). The study was approved by the Institutions' Review Boards. All patients provided written informed consent for data collection; patients with learning disability were included after consent from a parent or guardian.
Demographic and clinical data on 917 patients were obtained from medical records and stored in an electronic database. Most of the data were retrospective, with further prospective data collection from the time of recruitment up to the last clinic visit. The following clinical features were collected: epilepsy and seizure types according to the latest classifications of the International League Against epilepsy (ILAE) [13, 14] , AED history, seizure frequency at the last follow-up, disease duration, presurgical assessment results, surgical epilepsy treatment and history of status epilepticus.
Patients were considered drug resistant if they had been treated with at least three different AEDs. The ILAE defined drug resistance as failure of adequate trials of two tolerated and appropriately chosen and used AED schedules to achieve sustained seizure freedom, defined as freedom from seizures for a minimum of three times the longest preintervention interseizure interval or 12 months, whichever is longer [15] . In practice, it often proves very difficult to define exact interseizure intervals and determine if AED trials were adequate and tolerated, especially in large sets of retrospectively collected data. Therefore, we here opted for a pragmatic interpretation of the ILAE definition of drug resistance, based on the assumption that patients having failed two AEDs will logically need treatment with a third AED. Among drug resistant patients, we identified patients undergoing presurgical evaluation and subsequent surgical treatment ( Fig. 1 ). Presurgical evaluation included high-resolution brain magnetic resonance imaging (MRI), long-term video-EEG monitoring, fluorodeoxyglucose (FDG)positron emission tomography (PET) and a comprehensive cognitive evaluation, with additional investigations such as invasive EEG recordings, Wada test, magnetoencephalography (MEG), psychiatric evaluation and ictal single-photon emission computed tomography (SPECT) when indicated. All cases were discussed during a multidisciplinary presurgical meeting. In patients undergoing surgical treatment, we collected further details on the type and timing of the intervention. For the purpose of this study, palliative surgical approaches such as VNS and DBS were included in the surgical treatment group. We report seizure outcomes of patients undergoing surgical treatment and those treated with further AED trials, obtained from the last follow-up visit. Seizure outcome was classified dichotomously as either "seizure free", defined as complete seizure freedom for at least one year, or "ongoing seizures", defined as occurrence of any seizure, following the ILAE definitions [15] . Seizure outcome of patients undergoing surgical treatment was additionally classified according to the ILAE classification [16] . In patients undergoing more than one surgical treatment we considered the latest intervention.
Finally we provide a detailed characterization of the subgroup of patients with ongoing seizures at last follow-up and compare features of this subgroup with those of patients who became seizure free.
Descriptive statistics (mean, frequencies, and proportions) were used to characterize demographic and clinical variables. Student's t-test or Mann-Whitney test were used to compare continuous variables and chi-square test or Fisher exac t-test for analysis of categorical variables. Data were analysed using IBM SPSS 20.0 statistical package.
Results
Detailed clinical information was available on 904 of 917 patients. Four patients with a diagnosis of isolated status epilepticus were excluded.
Characteristics of patients with DRE
Six hundred and forty of 900 patients (71.1%) fulfilled the criteria of DRE. Three hundred and sixty-seven (57.3%) of these 640 patients were female. Mean age at last follow-up visit was 44.5 (standard deviation [SD] 15.3) years. Mean age at epilepsy onset was 20.5 (SD 16.6) years and mean disease duration 23.9 (SD 15.6) years. The mean number of AED trials was 6.3 (SD 3.2). Five hundred and twelve (80.0%) drug resistant patients had a diagnosis of focal epilepsy, with an identified structural lesion in 314. Eighty-eight patients (13.8%) had isolated, unilateral hippocampal sclerosis. Sixty-six (10.3%) had generalized epilepsy and 62 (9.7%) had unknown or combined epilepsy types. Further clinical details of the study population are provided in Supplementary Table 1 . Fig. 1 shows the treatment trajectories and seizure outcomes of the 640 patients with DRE.
Patients undergoing surgical treatment
Presurgical evaluation was performed in 249 patients (38.9%). One Table 2 ). The most frequent underlying pathologies were hippocampal sclerosis (n = 55), brain tumors (n = 41), cavernoma (n = 12) and malformation of cortical development (n = 11). Mean follow-up duration after surgical treatment was 7.8 years (SD 6.5). Eighty six patients (13.4% of all drug resistant patients) were seizure free at last follow-up (ILAE classes 1 and 1a). Rates of seizure freedom according to type of surgical treatment are shown in Table 1 .
Among patients with ongoing seizures, 10 (5.1%) had ILAE class 2 outcome, 12 (6.1%) had class 3 outcome and 89 (45.2%) had class 4-6 outcome ( Supplementary Table 3 ). Of 24 patients undergoing more than one surgical treatment procedure, seizure outcome was classified as 1 or 1a in 10 (41.7%), 3 in four patients (17.6%) and 4 to 6 in 10 patients (41.7%). The percentage of seizure free (ILAE classes 1/1a) versus non seizure free (ILAE classes 2-6) patients was not significantly different in patients undergoing one versus multiple surgical treatment procedures ( Supplementary Table 4 ). Among patients with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) undergoing surgical treatment, 35/55 patients (63.6%) were seizure free at last follow-up, with a mean follow-up duration of 8.6 years (SD 5.9). Seizure freedom rates per type of treatment are presented in Table 2 . Patients with malformation of cortical development were significantly less likely to be rendered seizure free compared to patients with hippocampal sclerosis (27.3 and 63.6%, respectively; p = 0.03) (Supplementary Table 5 ). Seizure freedom rates in patients with brain tumor or cavernoma were not significantly different from those with other etiologies.
Patients treated with further AED trials
In the 443 drug resistant patients (69.2%) not undergoing surgical treatment and treated with further AED trials, 163 (25.5% of 640 drug resistant patients) became seizure free: 9/52 who had previously undergone presurgical evaluation but no subsequent surgical treatment and 154/391 of those without presurgical evaluation ( Fig. 1 ). Of 33 patients with MTLE-HS in this group, 10 became seizure free and 23 had ongoing seizures. 
Characteristics of patients with ongoing seizures
Of all 640 patients with DRE, treated by various combinations of pharmacological treatment with or without additional surgical procedures, 391 (61.1%) had ongoing seizures at last follow-up. Demographic and clinical features of this group are summarized in Table 3 .
Patients with focal epilepsy represented the largest group (N = 317, 81.1%), with an identified structural lesion in 176 (45.0%). The most frequent underlying pathologies were hippocampal sclerosis (n = 43; 11.0%) and brain tumors (n = 37; 9.5%). One hundred and thirty-four (34.3%) patients had at least one focal impaired awareness seizure per month and 74 (18.9%) had at least one tonic-clonic seizure per month.
Patients with ongoing seizures had significantly higher numbers of AED trials compared to seizure free patients (6.9 ± 3.4 versus 5.4 ± 2.6, p < 0.0001). Patients with hippocampal sclerosis were significantly overrepresented in the seizure free group, while patients with malformation of cortical development and those with temporal lobe epilepsy of unknown etiology were significantly overrepresented in the group with ongoing seizures.
Discussion
Despite the availability of a large array of AEDs, DRE remains a commonly encountered problem, especially in tertiary referral centers. In addition, only a proportion of patients with DRE are suitable candidates for resective surgery [18] . Neuromodulation and ablative procedures result in seizure freedom in small to modest proportions of patients [10] . Therefore, the burden of uncontrolled epilepsy remains high. In contrast with previous studies reporting treatment outcomes in patients with DRE, our study aimed to assess the overall impact of currently available pharmacological and surgical epilepsy treatments on seizure outcome in patients with DRE followed over a prolonged time. From a patient's perspective, knowledge of the probability of attaining seizure freedom, irrespective of treatment modality, and the factors influencing outcome are of primordial importance. For the same reason we decided to include palliative surgical approaches such as VNS and DBS in the surgical treatment group, since such procedures would be regarded by most patients as surgical interventions, even if it is well known that outcomes with these procedures are very different from those of resective surgery.
We provide a detailed characterization and describe treatment trajectories of patients with DRE followed at two reference centers for DRE in Belgium. In addition, we report long-term seizure outcomes of patients with DRE treated by the various AEDs and surgical treatment modalities currently available in most developed countries. Our findings demonstrate that despite the availability of a wide variety of pharmacological and surgical treatments, over 60% of patients are not rendered seizure free.
Of 640 patients with DRE, 249 (38.9%) underwent a complete presurgical evaluation. Reasons for not performing a presurgical evaluation may vary and include both patient and physician related factors [19] , e.g. presence of infrequent or mild seizures, multifocal or poorly localized seizures, evidence of a generalized or mixed epilepsy syndrome, and presence of bilateral or multifocal lesions on MRI. Of the 249 patients undergoing complete presurgical evaluation, 197 (79.1%) underwent surgical treatment. Again, the decision not to perform a surgical intervention after undergoing presurgical evaluation may be influenced by various factors, including unwillingness to undergo intracranial EEG exploration or to accept surgical risk, the presence of discordant findings or inability to define a clear epileptogenic zone [18, 20] .
Overall, 43.6% of patients undergoing surgical treatment were seizure free at last follow-up. Our cohort consisted of patients with heterogeneous epilepsies of various etiologies, undergoing a range of different procedures. Therefore, our results cannot be directly compared with those of other studies. Even within subgroups of patients, studies are often difficult to compare due to differences in the ways outcomes are measured and defined, different durations of follow-up, and differences in surgical techniques. Duration of follow-up in our study was longer than in most other studies. In the group of 109 patients undergoing resective surgery, 53.2% were seizure free after a median followup of 7.8 years, a figure comparable with that of most other studies [21] [22] [23] [24] . Seizure freedom rate in the group of 29 patients treated with mesial temporal disconnection was 69%, comparable with our previously reported results [17] . Of 46 patients treated with VNS, 10.9% were seizure free at a mean follow-up duration of 6.9 years. This rate of seizure freedom is relatively high, although a recent large study and meta-analysis reported seizure freedom rates of 8.2% at four years follow-up [25] . Numbers of patients treated with radiosurgery or DBS were too small to draw any firm conclusions. The rate of seizure freedom in the subgroup of patients with MTLE-HS undergoing resective surgery (67.7% at a mean follow-up of 8.2 years) is in line with that of most previous studies [26] [27] [28] . Twenty-four patients underwent more than one surgical procedure. Seizure outcome in this subgroup was not significantly different from that of patients undergoing a single intervention. The literature on this specific issue is sparse and hampered by small data samples. One study reported Engel class 1 outcome in 27.8% of patients with failed surgery subsequently undergoing either reoperation or neurostimulation [29] .
The percentage of drug resistant patients becoming seizure free with further AED trials (163/443 patients, 36.8%) is relatively high compared to those of previous studies of AED treatment in patients with DRE [4, 30] , however these studies were limited to patients presenting more than one seizure a month, thus representing a more severely affected population than in the present study. Our definition of DRE was based on the ILAE definition and therefore did not require a minimum seizure frequency. A large recent study in patients with incident DRE reported prolonged seizure freedom in 31% of patients [31] . Due to the mostly retrospective nature of our data, we cannot exclude that a proportion of AED failures was due to intolerance rather than inefficacy and therefore that some patients were not truly drug resistant. However, since the mean number of AED trials was 6.3 this percentage is likely small. The percentage of seizure freedom in patients who had undergone presurgical evaluation but no subsequent surgical treatment (17.3%) is comparable to the 21% reported previously in a comparable group of 34 patients [32] .
Overall, over 60% of all patients with DRE had ongoing seizures at last follow-up. In a comparable study of 246 patients with DRE treated with AEDs and/or surgery, but restricted to patients presenting at least one seizure per month, 24% attained 12-month seizure remission after a median follow-up of 5.9 years, with an estimated cumulative probability of 34.6% at seven years [30] . Patients with ongoing seizures represent a severely affected group, exhibiting frequent seizures and often undergoing numerous treatment trials. Morbidity and mortality are known to be significantly increased in this population [33] . Moreover, several studies have demonstrated that the cost of DRE is significantly higher compared to that of controlled epilepsy [34, 35] . Seizure outcomes were significantly different for a number of epilepsy types. Patients with focal structural epilepsy, and in particular those with MTLE-HS, were more likely to be seizure free compared to patients with other epilepsy types. Although our results cannot be directly compared to those of other studies, they reflect the well-known favourable outcome of surgery in MTLE-HS [9, 23] . Patients with focal epilepsy due to a malformation of cortical development or focal epilepsy of unknown etiology were more likely to have ongoing seizures, in line with the previously reported less favourable prognosis of these epilepsy types after resective surgery [9, 23, 36] . On the other hand, the generally more favourable outcome of surgery in temporal lobe epilepsy of unknown etiology as compared to extra-temporal lobe epilepsy is not confirmed here. This may be due to the fact that in our study only a minority of patients with these epilepsy types underwent surgery.
Conclusion
Our findings demonstrate that, despite the broad range of treatments for epilepsy already available, there remains a scope for further development of novel treatments for epilepsy, including both pharmacological and surgical approaches. Following recent developments in identification of biomarkers and machine learning [37] [38] [39] , it seems likely that these future treatments will be targeted at specific subgroups of patients with DRE.
Large, preferably prospective studies of DRE are warranted, to identify more accurately subgroups of patients that are unlikely to become seizure free with current treatment options and are amenable to selective, novel treatments.
